Короткий опис (реферат):
One of the urgent problems of modern hepatology remains the treatment of patients
with chronic viral hepatitis C, which is associated with an increase in the incidence and
development of complications - cirrhosis of the liver and hepatocellular carcinoma. The
presence of non-alcoholic fatty liver disease in patients accelerates the progression rate of
HCV infection and reduces the effectiveness and tolerability of antiviral therapy. The above
circumstances initiated us to the search for new non-drug technologies for the treatment of
this category of patients. The work aimed to evaluate the effectiveness of the integrated use
of standard antiviral therapy, drinking silicon low-mineralized sodium bicarbonate mineral
water, and EHF-therapy in patients with chronic viral hepatitis C with concomitant nonalcoholic fatty liver disease. We used the following methods: anamnestic, general clinical,
biochemical, serological, immunological, Ultrasonographic examination of the digestive
organs. We examined 42 patients who were divided into two groups. The control group (22
people) received the basic treatment complex, which included dietary nutrition, standard
antiviral therapy for 12 months, and an internal intake of mineral water during the first month of treatment. The main group (20 people), in addition to the basic complex of treatment,
additionally received EHF-therapy procedures for three months. Evaluation of the
effectiveness of treatment was carried out after 1 and 3 months from the start of treatment.
The treatment was accompanied by the positive dynamics of most signs of the disease in both
groups, with a predominance of EHF-therapy. In patients of main group, the disappearance of
complications of antiviral therapy was established - the absence of cytopenic syndrome,
normalization of immunological status, stimulation of interferonogenesis, restoration of
equilibrium in the lipid peroxidation system and antioxidant system. These positive results
made it possible to complete the course of therapy for all patients and obtain a virological
response in 50% of patients.
